Skip to main content
Retour
CNVVF logo

ConvaTec Group Plc

Qualité des données : 100%
Suracheté
CNVVF
OTC Healthcare Medical - Instruments & Supplies
3,40 €
0,00 € (0,00%)
Cap. Boursière : 6,63B
Également cotée sous CNVVY OTC
Fourchette du Jour
3,40 € 3,65 €
Fourchette 52 Semaines
2,78 € 3,95 €
Volume
100
Moyenne 50J / 200J
3,15 € / 3,23 €
Clôture Précédente
3,40 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 37,1 0,3
P/B 4,4 3,0
ROE % 11,2 3,7
Net Margin % 7,2 3,8
Rev Growth 5Y % 5,2 10,0
D/E 1,1 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 0,32 €
0,30 € – 0,33 €
 3,40B 1
FY2029 0,28 €
0,27 € – 0,29 €
 3,14B 1
FY2028 0,25 €
0,24 € – 0,26 €
 2,91B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-24 0,10 € 0,04 € -64,8%
2025-02-26 0,08 € 0,05 € -34,1%
2024-07-30 0,07 € 0,04 € -44,9%
2024-03-06 0,06 € 0,04 € -38,5%
2023-06-30 0,06 € 0,03 € -52,0%
2023-03-09 0,06 € 0,04 € -39,5%
2022-12-31 N/A 0,01 € —
2022-06-30 0,06 € 0,02 € -62,8%

Dividend History

Yield

0,02%

Payout Ratio

N/A

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 5,17% annually over 5 years — modest growth
ROE of 11,15% — decent returns on equity
Generating 342,45M in free cash flow
P/E of 37,05 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,74%
Cash machine — converts 191,43% of earnings into free cash flow

Croissance

Revenue Growth (5Y)
5,17%
Revenue (1Y)8,91%
Earnings (1Y)-6,09%
FCF Growth (3Y)19,90%

Qualité

Return on Equity
11,15%
ROIC9,95%
Net Margin7,18%
Op. Margin16,69%

Sécurité

Debt / Equity
1,06
Current Ratio1,53
Interest Coverage5,81

Valorisation

P/E Ratio
37,05
Forward P/EN/A
P/B Ratio4,36
EV/EBITDA19,63
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8,91% Revenue Growth (3Y) 7,88%
Earnings Growth (1Y) -6,09% Earnings Growth (3Y) 17,17%
Revenue Growth (5Y) 5,17% Earnings Growth (5Y) 11,06%
Profitability
Revenue (TTM) 2,49B Net Income (TTM) 178,89M
ROE 11,15% ROA 4,72%
Gross Margin 55,19% Operating Margin 16,69%
Net Margin 7,18% Free Cash Flow (TTM) 342,45M
ROIC 9,95% FCF Growth (3Y) 19,90%
Safety
Debt / Equity 1,06 Current Ratio 1,53
Interest Coverage 5,81
Dividends
Dividend Yield 0,02% Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 37,05 Forward P/E N/A
P/B Ratio 4,36 P/S Ratio 2,66
PEG Ratio -6,70 Forward PEG N/A
EV/EBITDA 19,63 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 5,17%
Market Cap 6,63B Enterprise Value 8,17B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,49B 2,29B 2,14B 2,07B 2,04B
Net Income 178,89M 190,50M 130,30M 62,90M 117,60M
EPS (Diluted) 0,09 0,09 0,06 0,03 0,06
Gross Profit 1,38B 1,28B 1,20B 1,12B 1,12B
Operating Income 416,05M 324,90M 262,70M 207,30M 203,60M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3,79B 3,52B 3,71B 3,59B 3,67B
Total Liabilities 2,27B 1,83B 2,02B 1,98B 1,98B
Shareholders' Equity 1,52B 1,69B 1,69B 1,61B 1,69B
Total Debt 1,61B 1,20B 1,31B 1,32B 1,44B
Cash & Equivalents 75,12M 64,70M 97,60M 143,80M 463,40M
Current Assets 941,50M 793,30M 870,00M 889,30M 1,11B
Current Liabilities 616,98M 512,30M 536,40M 533,10M 569,20M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#652 of 1052
39

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026